Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Friday 09 July, 2021

Omega Diagnostics Gp

AbC-19 rapid antibody test performance evaluation

RNS Number : 7496E
Omega Diagnostics Group PLC
09 July 2021


("Omega" or the "Company" or the "Group")


AbC-19TM rapid antibody test performance evaluation

Peer-reviewed performance evaluation and self-test user experience of AbC 19TM


Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes

the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, welcoming the publication of two peer-reviewed studies conducted by Ulster University and involving AbC-19™, a lateral flow test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus.


Highlights from the studies include:

· Excellent laboratory validation performance metrics for the AbC-19™ rapid test for SARS-CoV-2 spike protein IgG antibody detection and semi-quantitative correlation with
laboratory ELISA methods assaying IgG antibodies to the spike protein of the SARS-CoV-2 virus.

· AbC-19™ showed sensitivity of 97.58% and specificity of 99.59% when using evaluation methods as defined by the MHRA for Target Product Profile of an antibody test.

· In addition, the study notes that IgG antibodies to the SARS-CoV-2 virus were detected 10 months after infection. Understanding the longevity of COVID-19 antibodies is important
both immunologically and in helping to guide pandemic exit protocols.

· Positive user experience score from 1,544 participants who used AbC-19™ as a 'self-test'


Professor Chris Molloy, Independent chairman of the UK Rapid Test Consortium said: "We are entering a phase of the pandemic where testing for immunity will become as or more important than testing for infection. Rapid, accurate immunity tests are therefore a critical tool for citizens and public health providers to embrace. 


"Development of multiple antibody tests, and semi-quantitative approaches will enhance this portfolio and enable the most rapid global recovery."


The UK-RTC press release can be read in full here:





Omega Diagnostics Group PLC

Colin King, Chief Executive 

via Walbrook PR

Kieron Harbinson, Group Finance Director

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t